Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic
Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive
Hetrombopag.